-
公开(公告)号：US08703202B2
公开(公告)日：2014-04-22
申请号：US11492373
申请日：2006-07-24
CPC分类号： A61K9/14 , A61K9/145 , A61K9/146 , A61K9/148 , A61K9/16 , A61K9/1623 , A61K9/1629 , A61K9/167 , A61K9/1676 , A61K9/19 , A61K9/20 , A61K9/2077 , A61K9/282 , A61K9/284 , A61K9/2866 , A61K9/48 , A61K31/192 , A61K31/216 , A61K31/22 , A61K31/365 , A61K31/40 , A61K31/405 , A61K31/44 , A61K31/505 , A61K31/66 , A61K2300/00
摘要： Disclosed is a pharmaceutically acceptable oral dosage form comprising fenofibrate, phospholipid, a buffer salt, a water-soluble bulking agent selected from maltodextrin, mannitol, and combinations thereof, a cellulosic additive, beads or crystals of a pharmaceutically acceptable water-soluble excipient support material, a polyvinylpyrrolidone or crospovidone, croscarmellose sodium, granular mannitol, sodium dodecyl sulfate, silicon dioxide, and a stearate, wherein the fenofibrate is in the form of microparticles, and wherein at least a portion of the phospholipid is coated on the surfaces of the fenofibrate microparticles, the phospholipid coated microparticles are embedded in a matrix comprising the water-soluble bulking agent, phospholipid that is not coated on the microparticles, the buffer salt and the cellulosic additive, and the matrix is coated on up to 100% of the surfaces of the beads or crystals of the excipient support material.
摘要翻译： 公开了包含非诺贝特，磷脂，缓冲盐，选自麦芽糖糊精，甘露糖醇及其组合的水溶性填充剂的药学上可接受的口服剂型，纤维素添加剂，药学上可接受的水溶性赋形剂载体材料的珠粒或晶体 ，聚乙烯吡咯烷酮或交聚维酮，交联羧甲基纤维素钠，颗粒状甘露醇，十二烷基硫酸钠，二氧化硅和硬脂酸盐，其中非诺贝特为微粒形式，并且其中至少一部分磷脂被涂覆在非诺贝特 微粒，将包含磷脂的微粒嵌入包含水溶性填充剂的基质，未涂覆在微粒上的磷脂，缓冲盐和纤维素添加剂，并且将基质涂覆在至多100％的表面上 赋形剂载体材料的珠粒或晶体。
-
公开(公告)号：US08586094B2
公开(公告)日：2013-11-19
申请号：US10428007
申请日：2003-05-02
CPC分类号： A61K9/14 , A61K9/145 , A61K9/146 , A61K9/148 , A61K9/16 , A61K9/1623 , A61K9/1629 , A61K9/167 , A61K9/1676 , A61K9/19 , A61K9/20 , A61K9/2077 , A61K9/282 , A61K9/284 , A61K9/2866 , A61K9/48 , A61K31/192 , A61K31/216 , A61K31/22 , A61K31/365 , A61K31/40 , A61K31/405 , A61K31/44 , A61K31/505 , A61K31/66 , A61K2300/00
摘要： Disclosed is a pharmaceutically acceptable oral dosage form comprising fenofibrate, phospholipid, a buffer salt, a water-soluble bulking agent selected from maltodextrin, mannitol, and combinations thereof, a cellulosic additive, beads or crystals of a pharmaceutically acceptable water-soluble excipient support material, a polyvinylpyrrolidone or crospovidone, croscarmellose sodium, granular mannitol, sodium dodecyl sulfate, silicon dioxide, and a stearate, wherein the fenofibrate is in the form of microparticles, and wherein at least a portion of the phospholipid is coated on the surfaces of the fenofibrate microparticles, the phospholipid coated microparticles are embedded in a matrix comprising the water-soluble bulking agent, phospholipid that is not coated on the microparticles, the buffer salt and the cellulosic additive, and the matrix is coated on up to 100% of the surfaces of the beads or crystals of the excipient support material.
摘要翻译： 公开了包含非诺贝特，磷脂，缓冲盐，选自麦芽糖糊精，甘露糖醇及其组合的水溶性填充剂的药学上可接受的口服剂型，纤维素添加剂，药学上可接受的水溶性赋形剂载体材料的珠粒或晶体 ，聚乙烯吡咯烷酮或交聚维酮，交联羧甲基纤维素钠，颗粒状甘露醇，十二烷基硫酸钠，二氧化硅和硬脂酸盐，其中非诺贝特为微粒形式，并且其中至少一部分磷脂被涂覆在非诺贝特 微粒，将包含磷脂的微粒嵌入包含水溶性填充剂的基质，未涂覆在微粒上的磷脂，缓冲盐和纤维素添加剂，并且将基质涂覆在至多100％的表面上 赋形剂载体材料的珠粒或晶体。
-
公开(公告)号：US20070259037A1
公开(公告)日：2007-11-08
申请号：US11824830
申请日：2007-07-02
申请人： Pol-Henri Guivarc'h , Gary Robinson
发明人： Pol-Henri Guivarc'h , Gary Robinson
CPC分类号： A61K9/4858 , A61K9/0014 , A61K9/4891 , A61K31/00 , A61K31/20 , A61K31/58
摘要： Methods of treating inflammation of the gastrointestinal tract and/or systemic or local inflammation by administering a steroid anti-inflammatory or a non-steroid anti-inflammatory drug in conjunction with polyunsaturated fatty acids or their derivatives and optionally also a pharmacologically active antioxidant and compositions for practicing these methods are described.
摘要翻译： 通过与多不饱和脂肪酸或其衍生物一起施用类固醇抗炎药或非类固醇抗炎药物以及任选还有药理活性的抗氧化剂和组合物来治疗胃肠道炎症和/或全身或局部炎症的方法 对这些方法进行了描述。
-
公开(公告)号：US20060257494A1
公开(公告)日：2006-11-16
申请号：US11492373
申请日：2006-07-24
IPC分类号： A61K31/192 , A61K9/14
CPC分类号： A61K9/14 , A61K9/145 , A61K9/146 , A61K9/148 , A61K9/16 , A61K9/1623 , A61K9/1629 , A61K9/167 , A61K9/1676 , A61K9/19 , A61K9/20 , A61K9/2077 , A61K9/282 , A61K9/284 , A61K9/2866 , A61K9/48 , A61K31/192 , A61K31/216 , A61K31/22 , A61K31/365 , A61K31/40 , A61K31/405 , A61K31/44 , A61K31/505 , A61K31/66 , A61K2300/00
摘要： Disclosed is a pharmaceutically acceptable oral dosage form comprising fenofibrate, phospholipid, a buffer salt, a water-soluble bulking agent selected from maltodextrin, mannitol, and combinations thereof, a cellulosic additive, beads or crystals of a pharmaceutically acceptable water-soluble excipient support material, a polyvinylpyrrolidone or crospovidone, croscarmellose sodium, granular mannitol, sodium dodecyl sulfate, silicon dioxide, and a stearate, wherein the fenofibrate is in the form of microparticles, and wherein at least a portion of the phospholipid is coated on the surfaces of the fenofibrate microparticles, the phospholipid coated microparticles are embedded in a matrix comprising the water-soluble bulking agent, phospholipid that is not coated on the microparticles, the buffer salt and the cellulosic additive, and the matrix is coated on up to 100% of the surfaces of the beads or crystals of the excipient support material.
-
公开(公告)号：US20120064160A1
公开(公告)日：2012-03-15
申请号：US13295708
申请日：2011-11-14
申请人： Pol-Henri Guivarc'h , Indu Parikh , Robert A. Snow
发明人： Pol-Henri Guivarc'h , Indu Parikh , Robert A. Snow
IPC分类号： A61K9/28 , A61K31/225 , A61K31/40 , A61K31/505 , A61P3/00 , A61K31/4418 , A61K31/47 , A61K9/14 , A61P3/06 , A61K31/366 , A61K31/405
CPC分类号： A61K45/06 , A61K9/145 , A61K9/1623 , A61K31/216 , A61K31/22 , A61K31/365 , A61K31/40 , A61K31/405 , A61K31/44 , A61K31/505 , A61K31/66 , Y10S424/824 , Y10S977/906 , A61K2300/00
摘要： This invention discloses an orally administered pharmaceutical composition for the treatment of elevated levels of cholesterol and related conditions comprising a statin and fenofibrate in the form of microparticles of solid fenofibrate that are stabilized by phospholipid as a surface active substance, wherein a therapeutically effective amount of the composition provides the statin and a quantity of fenofibrate to a fasted human patient that is greater than 80% of the quantity of fenofibrate provided by the same amount of the composition when administered to the same patient who has been fed a high fat meal.
摘要翻译： 本发明公开了一种口服给药的药物组合物，用于治疗胆固醇水平升高和相关病症，包括以磷脂作为表面活性物质稳定的固体非诺贝特微粒形式的他汀类药物和非诺贝特，其中治疗有效量的 组合物向给予高脂肪膳食的同一患者施用时，对禁食的患者提供了他汀类药物和一定量的非诺贝特，其大于由相同量的组合物提供的非诺贝特量的80％。
-
-
-
-
搜索结果
5 条记录 (耗时 0.018 秒)
